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ORIGINAL ARTICLE
A cross-sectional study in young adults with psoriasis: potential determining
factors in quality of life, life course and work productivity
Inge M. G. J. Bronckers, Maartje J. van Geel, Peter C. M. van de Kerkhof, Elke M. G. J. de Jong and
Marieke M. B. Seyger
Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
ABSTRACT
Background: Psoriasis can have a substantial impact on health-related quality of life (HRQoL), life course,
and work productivity. Young adulthood is a critical, sensitive period of development that includes major
life changing decisions. The impact of psoriasis on this vulnerable population is yet unknown.
Objectives: To assess QoL, life course, and work productivity in young adults with psoriasis and identify
characteristics influencing these patient-reported outcomes (PRO).
Methods: An explorative, cross-sectional study was performed in psoriasis patients aged 18–30 years.
Individuals completed a set of questionnaires regarding their health status (DLQI, SF-36, EQ-5D), achieve-
ment of developmental milestones (COLQ), and work productivity (WPAI-PSO, PRODISQ).
Results: Seventy-five patients (22 males, 53 females; median age [IQR], 21.0 [8.0]). Median PASI and BSA,
respectively, were 4.4 [4.9] and 4.5 [8.4]. Young adults experienced feelings of embarrassment, impair-
ments in physical health and work productivity, and difficulties in social development. Patients with more
severe psoriasis, longer disease duration, higher body mass index (BMI), female patients and patients
closer to their thirties tended to be more affected.
Conclusion: In the young adult psoriasis population, substantial QoL impairments were found. Female
patients, patients with high BMI, or long disease duration in particular tended to experience more difficul-
ties. These exploratory findings indicate the need for further studies in young adults to detect potential
clinical predictors for severe HRQoL impairments.
Abbreviations: BMI: body mass index; BSA: body surface area; CLCI: cumulative life course impairment;
COLQ: course of life questionnaire; DLQI: dermatology life quality index; EQ-5D: European Quality of Life-5
Dimensions; GH: general health; HRQoL: health-related quality of life; MCS: mental component summary;
MH: mental health; MLCD: major life changing decision; PASI: psoriasis area and severity index; PCS: phys-
ical component summary; PEER: psoriasis empowerment enquiry in routine practice; PGA: physician global
assessment; PF: physical functioning; PRO: patient-reported outcome; PRODISQ: productivity and disease
questionnaire; RE: role emotional; RP: role physical; QoL: quality of life; SF: social functioning; SF-36: Short
Form Health Survey; VAS: visual analog scale; VT: vitality; WMO: wet medisch-wetenschappelijk onderzoek
met mensen; WPAI-PSO: Work Productivity and Activity Impairment Questionnaire: Psoriasis
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Introduction
Psoriasis can have a substantial impact on health-related quality of life
(HRQoL), encompassing individual’s well-being from physical, psycho-
logical, social, occupational, and treatment perspectives (1,2). To date,
almost 60% of patients consider psoriasis to have a major impact on
their life quality (3–5). The impact on HRQoL has even been shown to be
comparable to that of depression, cardiovascular disease, and cancer (6).
Psoriasis develops before 18 years of age in approximately one
third of the adult psoriasis population, with the majority having
disease onset in adolescence. The psychosocial impact of psoriasis
on the young adult population (aged 18–30 years), however, is
relatively unknown (7–9).
Young adults develop their personality, plan career trajectories,
establish social contacts and face major life changing decisions
(MLCDs) relating to education, career choice, and social relation-
ships (9,10). Accordingly, young adulthood has been postulated as a
critical and sensitive period, in which psoriasis may even have a
greater impact on quality of life (QoL) and ultimately on patients’
life course than in older age groups (11,12).
Kimball et al. proposed the concept of ‘cumulative life course
impairment’ (CLCI) to indicate the cumulative effect of psoriasis and
its associated comorbidities and stigma over patients’ life course.
CLCI results from interaction between lifelong effects of stigmatiza-
tion, physical and psychological comorbidities, coping strategies,
and external factors (13). Although the exact risk factors for CLCI
and their relative contribution to cumulative impairment have yet
to be established, it is reasonable to state that disease onset in ado-
lescence or young adulthood, has a greater impact on life potential
than late onset psoriasis (14). The fact that MLCDs affected by
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psoriasis add up to this cumulative impairment supports this
hypothesis (15,16).
Psoriasis also has considerable economic consequences for the
working-age population including young adults. Nearly half of
patients regularly miss work due to their psoriasis or psoriasis treat-
ments and work productivity is decreased compared to healthy
individuals (4,17,18). These effects can result in reduced socioeco-
nomic standing and limitations in obtaining the necessary services
for treatment (19). Conversely, patients with moderate psoriasis
have concerns with time and costs of psoriasis treatments, which
can ultimately affect their work and insurance status (20).
Patient-reported outcomes (PROs) are increasingly part of clin-
ical research and daily clinical practice to understand the impact
of psoriasis on QoL (21,22). Nonetheless, the impact of psoriasis in
young adulthood is relatively unknown. This study was performed
to assess QoL, life course (as determined by the achievement of
developmental milestones) and work productivity in young adults
with psoriasis and to explore patient and/or disease characteristics
contributing to these impairments in order to provide directions
for further research in this vulnerable population.
Materials and methods
Study design and population
An explorative, cross-sectional, prospective, non-interventional
study was performed to assess the impact of psoriasis on HRQL in
young adults. Participants were recruited between May 2014 and
March 2015, from all patients with psoriasis who were seen at the
outpatient clinic of the Department of Dermatology, Radboud
University Medical Center. Inclusion criteria included age
18–30 years and a history of plaque psoriasis. Diagnosis was con-
firmed by a dermatologist. The study has been carried out in the
Netherlands in accordance with the applicable rules concerning
the review ethics committees and informed consent.
Data collection and management
Demographic information and psoriasis characteristics, including
psoriasis severity scores (psoriasis area and severity index (PASI),
body surface area (BSA), and physician global assessment (PGA))
antipsoriatic treatments received up to inclusion and the presence
of comorbidities, were collected. All participants completed a set
of PRO questionnaires concerning the impact of psoriasis on their
life at the time of enrollment.
PRO measurements
Quality of life
To measure the impact of psoriasis on important aspects of QoL,
the following questionnaires were used: dermatology life quality
index (DLQI), Short Form Health Survey (SF-36), and European
Quality of Life-5 Dimensions (EQ-5D).
The DLQI is a 10-question validated questionnaire that meas-
ures the degree to which a patient’s life is affected by his/her skin
condition over the last week (23,24). Total score ranges from 0 to
30; higher scores indicate greater impairment. If two or more
questions are left unanswered the questionnaire is not scored.
The SF-36 is a generic, 36-item, self-report health status question-
naire assessing eight domains of health status (25). A score from
0 to 100 is calculated for each domain (Table 3), with higher
scores indicating better QoL. The SF-36 includes both cross-sec-
tional and longitudinal components evaluating physical and psy-
chological functioning. Different domains are summarized in a
physical component score (PCS) consisting of physical functioning
(PF), role physical (RP), general health (GH), and vitality (VT) scores
and in and mental component score (MCS) consisting of VT, social
functioning (SF), role emotional (RE), and mental health (MH).
Norm-based scoring is incorporated in statistical analyses to com-
pare PCS and MCS values to the general Dutch population norm.
This population norm is set at a mean (SD) score of 50 ± 10.
The EQ-5D is another standardized generic instrument that
measures five dimensions of health with three levels per dimen-
sion (26). Total score ranges from 0 to 15; higher scores reflecting
worse health state on surveyed day. The EQ-5D also includes a
visual analog scale (VAS) and a Dutch population-based EQ-5D
index score.
Life course: achievement of developmental milestones
The course of life questionnaire (COLQ) was used to assess the
achievement of developmental milestones in our study population.
This aspect has been studied in different chronic diseases but never
in psoriasis. Items are divided into five scales and concern the
behavior characteristics of certain stages of development, psycho-
social developmental tasks and limitations children might experi-
ence when growing up with a chronic disease (27,28). Three out of
the five scales were used in our study: (1) autonomy development,
(2) psychosexual development, and (3) social development. A higher
scale score indicates the accomplishment of more developmental
milestones and hence a more favorable course of life.
Work productivity
The Work Productivity and Activity Impairment Questionnaire:
Psoriasis (WPAI-PSO) instrument is a 6-item questionnaire used to
assess work productivity and activity impairment related to skin
psoriasis over the past week (29). Scores are expressed in percent-
age of impairment (0–100). In order to estimate patients’ working
situation and absenteeism (work time missed) in the last three
months, we included module B and C of the PROductivity and
DISease Questionnaire (PRODISQ), a valid instrument to measure
productivity costs (30).
Statistical analysis
Descriptive statistics, including medians and interquartile ranges
[IQR] for continuous variables and numbers and percentages
(No.(%)) for categorical data, were used to explore demographic
and psoriasis characteristics. Univariable relations between con-
tinuous outcome measures and possible determining factors were
studied using the Mann–Whitney U test and Kruskal–Wallis H test
for categorical predictors, and Spearman’s rank correlation coeffi-
cients for continuous predictors. Multivariable general linear mod-
eling was performed to further determine predicting factors for
each outcome measure. Model assumptions for the generalized
linear model (GLM) were reasonably met. Residuals were normally
distributed and the assumption of homoscedasticity was met. p
values .05 (two-sided) were considered statistically significant.
The statistical package SPSS version 22.0 (IBM, Armonk, NY, USA)
was used to perform all statistical analyses.
Results
Study patients
Demographic information and clinical characteristics are shown in
Table 1. The cohort consisted of 75 patients (22 males (29.3%)
and 53 females (70.7%)), with a median age of 21.0 [8.0] years.
Median PASI and BSA scores were respectively 4.4 [4.9] and 4.5
[8.4]. Median age at diagnosis was 13.0 [5.0] years; 88.0% were
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diagnosed with psoriasis in childhood. Median body mass index
(BMI) was 23.4 [6.9] kg/m2. With respect to their current treat-
ment, 38.7% received systemic therapy and 12.0% were treated
with biologics (Table 2). Five patients (6.7%) had psoriatic arth-
ritis (PsA).
Quality of Life
Patients reported a median total DLQI score of 4.0 [7.0], with the
impact of psoriasis interpreted as having ‘no or small effect on
QoL’ (score 0–5) in 59.2% of our cohort and ‘moderate to extreme
large effect on QoL’ (score 6–30) in 40.8%. Four patients left two
or more questions unanswered and were therefore excluded.
Highest scores were reported on the subscale ‘symptoms and
feelings’, reflecting pain, itch and feelings of embarrassment, or
self-consciousness (Table 3). Psoriasis severity and female sex
were associated with a higher total DLQI score through univari-
able and multivariable analysis (PGA: B¼ 1.76; confidence interval
(CI) 0.55, 2.98; p¼ .005 and sex (female vs. male): B¼ 2.92; 95%CI
0.04, 5.89; p¼ .053) (Table 4). In accordance with total DLQI, the
DLQI subscale score ‘social functioning’ was also higher in females
(B¼12.00; 95%CI 23.32, 0.67; p¼ .04). This score reflects the
impact of psoriasis on friendships and social activities.
Patients’ GH status in previous weeks was assessed by the SF-
36 and EQ-5D. Median SF-36 PCS and MCS were 53.82 [7.91] and
52.32 [9.80], respectively, just above the general population norm
(31). BMI and disease duration were negatively correlated with
this PCS, indicating more physical impairment if patients suffered
from higher BMI or psoriasis for a longer period. Multivariable
analysis showed consistent results for disease duration (B¼0.39;
95%CI 0.68, 0.09; p¼ .012) (Table 4). Although no determining
factors were found for MCS, lowest scores reported on SF-36
domains contributed to this score instead of the PCS: VT (65.00
[30.00]), GH perception (72.00 [25.00]) and MH (80.0 [17.00])
(Figure 1). Median EQ-5D VAS score, indicating patient’s health
status on surveyed day, was 80.00 [20.00]. Higher BMI corre-
sponded to worse health care state in our young adult population
(B¼0.97; 95%CI 1.54, 0.40; p¼ .001) (Table 4).
Achievement of developmental milestones
The accomplishment of certain psychosocial developmental mile-
stones was evaluated by the COLQ. Scale scores for autonomy
development, psychosocial development, and social development
were respectively 9.00 [2.00], 8.00 [2.00], and 22.00 [3.00] (Table
3). With respect to social development, higher psoriasis severity
scores and more advanced age corresponded to the achievement
of fewer milestones in the social domain (e.g. contacts with peers)
(Table 4). Males tended to be less likely to achieve milestones of
psychosexual development compared to females (e.g. relation-
ships and sexual intimacy) (B¼ 1.05; 95%CI 0.03, 2.07; p¼ .045).
Work productivity
Among patients with paid work (N¼ 51), number of working
hours per week was 28.0 [28.0]. Psoriasis negatively affected work
productivity in 42.2% of young adults with paid work. Mean work
impairment because of reduced productivity due to psoriasis was
20.0% within the last 7 days. Limitations in the ability to do regu-
lar activities, such as studying and exercising, were reported by
59.2% of patients surveyed. Sick leave from work over the past 3
months was reported by 21.6% of patients (Table 5).
Discussion
The use of PRO measures to understand the impact of psoriasis
on QoL has become increasingly important over the years and is
essential for the development of optimal treatment strategies.
However, QoL in young adults with psoriasis has received little
attention so far. With approximately one third having disease
onset before 18 years of age and young adulthood being a critical
and sensitive period, young adults represent an important and
challenging patient population (9).
Table 1. Patient characteristics (N¼ 75).
Characteristic No. (%)a
Age, median [IQR], years 21.0 [8.0]
Sex
Male 22 (29.3)
Female 53 (70.7)
Duration of psoriasis, median [IOR], years 8.0 [8.0]
Age at diagnosis, median [IQR], years 13.0 [5.0]
Psoriasis onset in childhood (<18 years) 66 (88.0)
Psoriasis severity, median [IOR]
PASI 4.4 [4.9]
BSA 4.5 [8.4]
PGAb 2.0 [1.0]
BMI, median [IOR], kg m2c 23.4 [6.9]
Smokingd 18 (24.0)
Alcohol consumption 48 (64.0)
Comorbiditiese
Overweight or obesity 8 (10.7)
Psoriatic arthritis 5 (6.7)
Psychiatric disorder 4 (5.3)
Diabetes mellitus 1 (1.3)
Auto-immune disorder 1 (1.3)
Family history
Psoriasis in parents or siblings 29 (38.7)
Psoriasis in extended family members 34 (45.3)
Psoriatic arthritis in parents or siblings 2 (2.7)
BMI: body mass index; BSA: body surface area; PASI: psoriasis area and severity
index; PGA: physician global assessment; PY: packed years.
aData are presented as number (percentage) of patients unless other-
wise indicated.
bThe PGA scores range from 0 (clear) to 5 (very severe).
cMajority of patients had a normal weight, overweight and obese.
dMedian number of cigarettes per day and packed years, respectively.
eMost common comorbidities were depicted. None of our patients had fatty
liver disease, hyperlipidemia, Crohn’s disease, hypertension.
Table 2. Treatment characteristics (N¼ 75).
Characteristic No. (%)
Current treatment
Topicala 54 (72.0)
UVB phototherapy 5 (6.7)
Systemic 29 (38.7)
Conventional systemic 23 (30.7)
Cyclosporine 0
Methotrexate 14 (18.7)
Fumaric acid 8 (10.7)
Acitretin 1 (1.3)
Biological 9 (12.0)
Etanercept 3 (4.0)
Adalimumab 6 (8.0)
Infliximab 0
Ustekinumab 0
Most intensive treatment receivedb
Topical 12 (16.0)
UVB phototherapy 21 (28.0)
Conventional systemic 29 (38.7)
Biological 13 (17.3)
LCD: liquor carbonis detergens; UVB: ultraviolet B.
aTopicals included primarily corticosteroids and vitamine D analogs.
bMost intensive psoriasis treatment received until study enrollment.
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This study describes the impact of psoriasis on adults aged
18–30 years and to identify those who were more severely
impaired and may require special attention. Approximately half of
our population was classified as having minimal to mild psoriasis
at enrollment (PGA score) with 38.7% receiving systemic treat-
ment and 6.7% suffering from PsA. Almost 90% of our patients
were diagnosed with psoriasis in childhood. Despite the relative
stable plaque psoriasis at time of inclusion, this young adult
population experienced impairments in QoL, the accomplishment
of social developmental milestones, and reduced work
productivity.
The observation that almost half of young adults reported a
moderate to extreme large effect of psoriasis on their QoL, with
highest scores on DLQI subscale ‘symptoms and feelings’ was
comparable with previous cross-sectional studies adults with mod-
erate to severe plaque psoriasis and palmoplantar psoriasis, and
also reported in children and adolescents (32–34). In accordance
with adult psoriasis and atopic dermatitis studies, female patients
and patients with more severe psoriasis seemed to do worse
(35,36), especially in terms of self-consciousness and problems
with daily activities. Characteristics that negatively affect QoL
should draw our attention because of the additional vulnerability
in young adulthood.
Although the overall health status measured by the SF-36 was
comparable to the healthy Dutch population aged 16–40, the
scores primarily reflecting the MH status (VT, GH perception, SF
and MH domain) were substantially lower (31). Again, there was a
trend towards young females being more affected than their
male peers with respect to SF. Overall physical health status
seemed to be negatively influenced by higher BMI. Despite the
described association of psoriasis with obesity in literature, it is
yet unknown whether high BMI is the precursor of psoriasis or
whether psoriasis leads to an increased BMI through either cyto-
kine release and/or lifestyle (37,38). Subjects with relatively stable
plaque psoriasis but higher BMI experienced more physical diffi-
culties (SF-36) and worse health state (EQ-5D). Even if these diffi-
culties are primarily the result of BMI, physical difficulties and
worse health state are part of a vicious circle in psoriasis patients
leading to more inactivity, aggravation of psoriasis, and ultimately
CLCI. In addition, longer duration of psoriasis reduced the overall
physical health status. Although the relation between age and
QoL is controversial (35), adaptation to psoriasis seemed to be
more difficult for young adults with longer disease duration, at
least in terms of their physical health status.
Since the cumulative effect of significant physical and psycho-
logical exposures at different time points in patient’s life can pro-
duce CLCI (13,14), we also evaluated the achievement of
developmental milestones. Even though the same milestones
have been achieved with respect to autonomy, social, and psy-
chosexual development compared to a healthy age- and sex-
matched control group in a former study by Stam et al. (39),
young adults with more severe psoriasis experienced more diffi-
culties on social development. This is in line with a study per-
formed in young adults with atopic dermatitis, and serves as
another point of concern for dermatologists in daily clinical prac-
tice (40). Our finding that males tended to be less likely to
achieve milestones of psychosexual development compared to
females has not been described by others.
The observation that psoriasis negatively affected work prod-
uctivity in 42.2% of our population with a productivity impairment
of 20.0%, reflects the impact of psoriasis on the young working
population who choose to see a dermatologist for their psoriasis
at a tertiary referral center. Work deterioration was related to
impairment at work (presenteeism) and missed work (absentee-
ism). Comparison with other working populations suffering from
psoriasis or other (skin) disease is difficult because of differences
in working organization between countries. Loss of productivity in
200 patients (mean age 51.4 years) with moderate to severe psor-
iasis enrolled in nine US sites, was estimated to be 14.2%, and
highest among patients with severe psoriasis. Patients with mild
psoriasis experienced only 1% impairment at work (17). A retro-
spective study in 694 psoriasis patients in the USA exploring the
Table 3. Patient-reported outcomes on QoL instruments.
Instrument Median [IQR]a
DLQI (N5 71)
Total score 4.0 [7.0]
Bands, No. (%)
0–5 42 (59.2)
6–30 29 (40.8)
Categories
Symptoms feelings (range 0–6) 2.0 [2.0]
Daily activities (range 0–6) 1.0 [2.0]
Leisure (range 0–6) 0 [2.0]
Work school (range 0–3) 0
Personal relationships (range 0–6) 0 [2.0]
Treatment (range 0–3) 0 [1.0]
SF-36 (N5 75)b
PCS 53.8 [7.9]
MCS 52.3 [9.8]
EQ-5D (N5 74)
EQ-5D utility indexc 1.0 [0.2]
EQ-5D VAS 80.0 [20.0]
E5-5D mobility, No. (%)d
No problems 65 (90.3)
Problems 7 (9.7)
EQ-5D self-care, No. (%)
No problems 72 (97.3)
Problems 2 (2.7)
EQ-5D daily activities, No. (%)
No problems 60 (81.1)
Problems 14 (19.0)
EQ-5D pain/discomfort, No. (%)
No problems 60 (81.1)
Problems 14 (19.0)
EQ-5D anxiety/depression, No. (%)
No problems 57 (77.0)
Problems 17 (23.0)
COLQ (N5 75)
Autonomy development (range 6–12) 9.0 [2.0]
Social development (range 12–24) 22.0 [3.0]
Psychosexual development (range 4–8) 8.0 [3.0]
Sociodemographics
Marital status (N¼ 66), No. (%)
Married/living together 20 (30.3)
Single 46 (69.7)
Education, No. (%)
High 33 (44.6)
Middle 39 (52.7)
Low 2 (2.7)
DLQI: dermatology life quality index; EQ-5D: European Quality of Life-5
Dimensions; IQR: interquartile range; MCS: mental component summary; PCS:
physical component summary; QoL: quality of life; SF-36: 36-item Short Form
Health Survey; VAS: visual analog scale.
aData are presented as median [IQR] unless otherwise indicated.
bThe eight scales of the SF-36 can be aggregated into two summary measures,
the PCS and MCS. The general Dutch population norm is set at a mean (SD)
score of 50.0 (10.0) (32).
cEuroQoL using the Dutch EQ-5D tariff. Scores reflect general health status and
range from 1 (full health) to 0 (dead), and below 0 for states worse than dead.
dPatients are asked to indicate his/her health status by choosing the most
appropriate statement (no problems, some problems, and extreme problems) in
each of the five dimensions. This statement expresses the level for that dimen-
sion on the surveyed day. Answers were dichotomized into ‘having no prob-
lems’ and ‘having problems’.
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relationship between psoriasis severity and work productivity
showed an overall work impairment of 7.4% in patients with mild
psoriasis to 22.9% in patients suffering from severe psoriasis (18).
The fact that young adults with relatively stable psoriasis experi-
enced more impairment at work than adult patients suffering
from mild psoriasis in previous studies, supports the hypothesis of
young adulthood being a critical period in which psoriasis can
even have more impact on QoL and work productivity. No com-
parable studies have been performed in working individuals aged
18–30 years with psoriasis or other skin disease. The majority of
MLCDs relating to career choice are made in young adulthood
and influenced by chronic skin disease (15). Young adults could
therefore be more vulnerable to occupational disabilities due to
psoriasis (33).
Our explorative, cross-sectional study was limited by the
absence of a control group, introducing certain confounding bias
by not eliminating external variables that can interfere with the
impact on QoL. In addition, there is a potential for selection bias,
as our study has been performed in a tertiary referral center.
Finally, outcome measures were obtained at one moment in time.
Though serial measurements would be of additional value, our
study had an explorative character and aimed to provide direc-
tions for future QoL studies in the young adult psoria-
sis population.
In conclusion, young adults with relatively stable plaque psor-
iasis experienced feelings of embarrassment, impairments in daily
activities, current physical health, and showed reduced productiv-
ity at work due to psoriasis. Female patients, patients with high
BMI and patients with long disease duration seemed to be more
severely impaired. Our findings underline the importance of the
use of PRO instruments to understand problems that young
adults with psoriasis meet, and emphasize the need for further
prospective, case–control studies in this population to ultimately
provide directions for better, patient-centered care. Physical symp-
toms as well as the more elusive psychosocial impact and its
prognostic factors have to be clearly defined in this population
and integrated into the discussion whether dermatologist should
treat young adults with conventional systemics or biologics in an
earlier stage of disease.
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Figure 1. Median Short Form Health Survey (SF-36) domain scores for patients
aged 18–30 years with psoriasis. The SF-36 is a generic, self-report health status
questionnaire assessing eight domains of health status. A score from 0 to 100 is
calculated for each domain, with higher scores indicating better quality of life
(QoL). BP: bodily pain; GH: general health; MH: mental health; PF: physical func-
tioning; RE: role emotional; RP: role physical; SF: social functioning; VT: vitality.
Table 5. Work situation, absence and work productivity in young adult psoriasis
patients (N¼ 51).
Instrument No. (%)a
PRODISQ
Work situation
Working hours per week, median [IQR] 28.0 [25.0]
Working days per week, median [IQR] 5.0 [2.0]
Irregular work shifts 23 (45.1)
Leading function 12 (23.5)
Absence
Absent from work in last 3 months 11 (21.6)
Number of days absent, median [IQR] 3.0 [6.0]
Number of periods absent, median [IQR] 1.0 [0.0]
WPAI-PSO
No. (%) of patients experienced impairment
Impaired work productivity due to psoriasis (N¼ 45) 19 (42.2)
Impaired activities due to psoriasis (N¼ 71) 42 (59.2)
Median [IQR] percentage impairment
Impairment caused by disease-related absenteeismb 50.0 [46.0]
Impairment while working owing to presenteeismc 20.0 [60.0]
Total activity impairment (N¼ 75)d 10.0 [30.0]
aValues are presented as number (percentage) of patients unless other-
wise indicated.
bCalculated as [hours absent from work due to psoriasis/(hours absent from
work due to psoriasisþ hours actually worked)] 100%.
cCalculated using visual analog scale as percentage reduced productivity
while working.
dCalculated using visual analog scale as percentage impairment in regular daily
activities other than working.
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